Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.25 (-1.79%)
Spread: 0.50 (3.704%)
Open: 14.00
High: 14.00
Low: 13.75
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re US Venture -- Aberro

17 Nov 2005 07:02

Angle PLC17 November 2005 For Immediate Release 17 November 2005 ANGLE PLC US VENTURE, ABERRO: PRODUCT IN BETA TRIALS ANGLE is delighted to announce that it has officially launched Aberro, asoftware testing company (formerly known as ContraSoft). Aberro is 57 per cent.owned by ANGLE and is ANGLE's first US venture founded since ANGLE's flotationin 2004. Aberro has developed a beta release of its product, AberroTest, which is in useat several companies. The product solves a number of issues in the softwareindustry and is expected to be released commercially later this year. Aberro ispreviewing the technology at STARWEST, the world's largest software testingevent, which is being held this week in Anaheim, California. A recent IDC report projected that in 2006, companies will spend over $1 billionon tools to help improve their software testing capabilities. Aberro's AdaptiveAutomated Testing delivers easy and rapid test creation, with no programmingskills required, coupled with low-cost execution that automatically adapts tochanges in the target application. With Aberro's technology, tests areautomatically created in a matter of minutes. This allows testers to find andrepair defects sooner and more easily, while reducing development costs andimproving overall software quality. In developing Aberro, ANGLE has assembled an experienced management team headedby CEO Douglas Smith and Vice President of Marketing Steve Lafferty. Smithjoined the company from ANGLE, where he served as an Entrepreneur in Residence.He has over 20 years of management experience, including CEO and COO roles atthree start-up companies and senior management positions at Digital Equipment,Compaq and EMC. Lafferty previously served as Business Unit Director withManugistics and has held senior-level marketing roles at Cadre, Iona, SterlingSoftware and Green Hills Software. Additionally, Aberro's Co-Founder and CTO William Rogers, Ph.D., brings over 20years of research and development experience to the team. Rogers was theoriginator of Aberro's revolutionary software testing technique, AdaptiveAutomated Testing, which enables rigorous automated testing of software farearlier than any other solution on the market. Rob Kornblum, Managing Director of ANGLE Ventures (US) said: "We are delighted with our progress at Aberro in delivering product to betausers so rapidly. We already see a tremendous amount of interest in Aberro'sproducts from the software community." For more information: ANGLE plc 01483 295830 Andrew Newland, Group CEO Buchanan Communications 020 7466 5000 Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)and operates from offices in the UK, the US and the Middle East. Further information can be found on www.ANGLEplc.com For more information on Aberro, please visit www.aberrosoftware.com or contactSteve Lafferty at 240.715 3333 x208. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
23rd Dec 20199:55 amRNSIssue of Equity
7th Nov 20197:00 amRNSCancer centre shows Parsortix use in melanoma
30th Oct 20192:44 pmRNSResult of AGM
30th Oct 20197:00 amRNSQ-submission to FDA containing headline data
8th Oct 20197:00 amRNSNotice of AGM
4th Oct 20195:54 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSEuropean patent granted for megakaryocyte analysis
13th Sep 20197:00 amRNSUse of Parsortix in head and neck cancer
10th Sep 20197:00 amRNSResearch with Parsortix in prostate cancer
4th Sep 20197:00 amRNSParsortix for Neuroendocrine Analysis in SCLC
29th Aug 20197:00 amRNSInitiation of Ovarian Cancer Study
31st Jul 20197:00 amRNSPrelim Results for the year ended 30 April 2019
22nd Jul 20197:00 amRNSUse of Parsortix for single cell analysis of CTCs
16th Jul 20199:19 amRNSHolding(s) in Company
12th Jul 201910:22 amRNSResult of General Meeting anf Total Voting Rights
28th Jun 20191:37 pmRNSNotice of Preliminary Results and Webcast
28th Jun 20191:08 pmRNSHolding(s) in Company
25th Jun 20195:19 pmRNSResult of Placing
25th Jun 20198:02 amRNSAccelerated bookbuild to raise £18.0m
21st Jun 20197:00 amRNSParsortix used to investigate immunotherapy target
5th Jun 20197:00 amRNSCompletion of Ovarian Cancer Pre-Study
31st May 20197:00 amRNSPositive Results from FDA Clinical Study
26th Apr 20197:00 amRNSIMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18th Apr 20197:00 amRNSParsortix used in new cancer assessment technique
12th Apr 20197:00 amRNSLUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
4th Apr 20197:00 amRNSAACR 2019
11th Mar 20197:00 amRNSHolding(s) in Company
7th Mar 20197:00 amRNSENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28th Feb 20197:00 amRNSFIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25th Feb 20197:00 amRNSCUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11th Feb 20197:00 amRNSResearch into role of immune cells in cancer
31st Jan 20197:00 amRNSInterim Results
29th Jan 20197:00 amRNSNEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11th Jan 20192:05 pmRNSSecond Price Monitoring Extn
11th Jan 20192:00 pmRNSPrice Monitoring Extension
11th Jan 201911:05 amRNSSecond Price Monitoring Extn
11th Jan 201911:00 amRNSPrice Monitoring Extension
11th Jan 20199:05 amRNSSecond Price Monitoring Extn
11th Jan 20199:00 amRNSPrice Monitoring Extension
10th Jan 20194:41 pmRNSSecond Price Monitoring Extn
10th Jan 20194:36 pmRNSPrice Monitoring Extension
10th Jan 20194:01 pmRNSBREAKTHROUGH CANCER RESEARCH USING PARSORTIX
9th Jan 20197:00 amRNSNotice of Results
21st Dec 20187:00 amRNSIssue of LTIP Options and Share Options
28th Nov 20187:00 amRNSLEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13th Nov 20185:10 pmRNSHolding(s) in Company
5th Nov 20187:00 amRNSAcquisition of outstanding shares
2nd Nov 20182:00 pmRNSPrice Monitoring Extension
1st Nov 20187:00 amRNSAppointment of Dr Jan Groen as NED
30th Oct 20184:21 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.